NASDAQ:QNRX

Quoin Pharmaceuticals Q4 2024 Earnings Results & Report

Quoin Pharmaceuticals logo
$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 +0.07 (+1.94%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quoin Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 13, 2025. The company reported EPS of -$12.25 versus the -$17.50 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens

Quoin Pharmaceuticals EPS Results

Actual EPS
-$12.25
Consensus EPS
-$17.50
Beat/Miss
Beat by +$5.25
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Quoin Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Quoin Pharmaceuticals Q4 2024 Earnings FAQ

Quoin Pharmaceuticals (NASDAQ:QNRX) reported earnings of -$12.25 per share for Q4 2024, beating the consensus estimate of -$17.50. The report was announced on Thursday, March 13, 2025.

Quoin Pharmaceuticals Earnings Headlines

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street Zen
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Quoin Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin.

Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

View Quoin Pharmaceuticals Profile